Xcout Intel
Angiocrine Bioscience, Inc. competitors & alternatives
The 12 closest competitors and alternatives to Angiocrine Bioscience, Inc. among life science companies — ranked by similarity to what Angiocrine Bioscience, Inc. actually does, not by market-cap band.
Subscribe to see Angiocrine Bioscience, Inc.’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
About Angiocrine Bioscience, Inc.
Angiocrine Bioscience, Inc. is a private, clinical-stage biotechnology company based in San Diego, California, that develops engineered endothelial cell therapies.
Angiocrine Bioscience, Inc. at a glance
Angiocrine Bioscience, Inc. is a life science company headquartered in United States, founded in 2012. It has raised at least $60.2M across the 2 funding rounds on record. Its most recent funding round raised $2.1M in August 2025. Xcout tracks 11 named people at Angiocrine Bioscience, Inc., including Paul Finnegan, M.D., M.B.A. (Chief Executive Officer).
Angiocrine Bioscience, Inc. leadership
- Paul Finnegan, M.D., M.B.A.Chief Executive Officer
- Paul W. Finnegan, M.D.President and CEO
- John R JaskowiakChief Operating Officer
- John LomoroChief Financial Officer
- John K. Fraser, Ph.D.Chief Scientific Officer
- John R JaskowiakExecutive Officer
5 more named people on record for Angiocrine Bioscience, Inc., with roles, board committees and tenure — see the full roster →
Angiocrine Bioscience, Inc. funding rounds
At least $60.2M raised across the 2 rounds on record. Every round on record:
| Date | Round | Amount | Investors |
|---|---|---|---|
| SEC Form D filing | $2.1M | — | |
| SEC Form D filing | $58.1M | — |
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
Top 12 Angiocrine Bioscience, Inc. competitors
Ranked by semantic similarity — how close each company is to Angiocrine Bioscience, Inc. by what it does, using Xcout's live company graph. Click any company for its full profile, or its competitor set.
Biotechnology
Metacrine, Inc. is a clinical-stage biopharmaceutical company headquartered in San Diego, California. The company builds a pipeline of differentiated therapies targeted at treating liver and gastrointestinal diseases.
Biotechnology
AcroCyte Therapeutics, Inc. is a biotechnology company dedicated to overcoming common laboratory challenges through its proprietary R³CE rapid, reproducible, rare cell 3D expansion technology. Recognized with awards such as the Taiwan National Innovation Award, the company focuses on advancing biomedical research and cell-based applications.
Biotech
Aspect Biosystems develops bioengineered cellular medicines and implantable tissue therapeutics using a proprietary bioprinting platform that integrates AI, computational design, and advanced biomaterials. The company serves the biotechnology and pharmaceutical industries by creating treatments to replace, repair, or supplement biological functions for metabolic and endocrine diseases.
Biotechnology
VST Bio Corp. is a leader in the development of innovative biologics to treat acute and chronic cardiovascular diseases. Headquartered in San Diego, California, the company engages in drug pipelines, patents, and clinical trials.
Biotechnology
Endogena Therapeutics, Inc. is a clinical-stage biotechnology company headquartered in Zürich, Switzerland, that discovers and develops first-in-class endogenous regenerative medicines to repair tissues.
Biotechnology
Autobahn Therapeutics is a biotechnology company headquartered in San Diego, California, focused on developing restorative treatments in the medical sector.
Biotech
Endsulin, Inc. is a biotechnology company developing a liver-directed gene therapy for Type 1 Diabetes. Its proprietary technology aims to re-engineer liver cells to restore the body's natural ability to produce and regulate insulin, eliminating the need for artificial insulin delivery methods.
Biotechnology
Aegle Therapeutics Corp. is a clinical-stage biotechnology company headquartered in Miami, Florida, with additional operations in Woburn, Massachusetts. The company is a leader in developing novel extracellular vesicle therapies to treat various diseases and disorders.
Biotech
Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.
Biotechnology
BioCrine AB is a drug pipeline and biotechnology research company headquartered in Solna, Sweden, operating in the endocrinology and therapeutic medical domains.
Biotechnology
BlueRock Therapeutics is a clinical-stage cell therapy company headquartered in Cambridge, Massachusetts, focused on developing engineered cellular medicines for degenerative conditions.
Analyze another company
Search any company we track to see its competitive set.
Or describe a company
Paste a short paragraph describing a company or product — we'll find the most similar companies we track, scored 1–100.
See the full profile of Angiocrine Bioscience, Inc. and its market
Funding, investors, tech stack, hiring signals, leadership and corporate events — for Angiocrine Bioscience, Inc.and every competitor above — in one live dashboard.
Subscribe to Xcout Intel →